Investor Presentation
April 2023 M&A: FlexBiosys meets Repligen's acquisition criteria
Complements and expands our
Fluid Management portfolio
Expands single-use Fluid Management
offerings; addresses a gap
In-house bag manufacturing and
integration into Repligen assemblies
O Further enables vertical integration
and supply chain control
R REPLIGEN
Provides operational and
commercial leverage
o Complement distributor network with
go direct strategy across regions
O Immediate opportunity to leverage
Repligen's global commercial team
(vs. limited commercial footprint)
o Supports assembly business growth at
newly established centers in
Hopkinton, MA and Waterford, Ireland
Strong revenue growth
potential
M&A
O COVID-19 related demand was
catalyst for expansion of capacity and
manufacturing capabilities
o $5M-$6M base business revenue
contribution expected in 2023 (9 mo.)
Business expected to grow at 25%
annually starting in 2024
o Expect acquisition to be accretive to
adjusted EPS in 2024
FLEX
FLEXBIOSYS
Flexible Design, Accelerating Your Results
16View entire presentation